Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trialJianxing He, Caicun Zhou, Chun Chen et al.|The Lancet Respiratory Medicine|2021Cited by 183
Household air pollution and epigenetic aging in Xuanwei, ChinaBatel Blechter, Qing Lan, Andrés Cárdenas et al.|Environment International|2023Cited by 26
miR-107 inhibited malignant biological behavior of non-small cell lung cancer cells by regulating the STK33/ERK signaling pathway in vivo and vitroXueqiang Wei, Yunchao Huang|Journal of Thoracic Disease|2020Cited by 21
The influences of TGF-β1 upon the human adenocarcinoma cell of lung A549 and cellular immunityMinjie Li, Yunchao Huang|Annals of Translational Medicine|2020Cited by 8
Rare mutations at EGFR L747 position: molecular characteristics and superior response to afatinib in NSCLC patientsYunchao Huang, Wen‐Feng Fang|ESMO Open|2025Cited by 0